

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF      ART UNIT: 1618  
RIGASSI-DIETRICH, PETRA GISELA ET AL.      EXAMINER: VU, JAKE MINH  
INTERNATIONAL APPLICATION NO: PCT/EP2005/002798  
FILED: MARCH 16, 2005  
U.S. APPLICATION NO: 10/590398  
35 USC §371 DATE: AUGUST 23, 2006  
FOR: GALENIC FORMULATIONS OF ORGANIC COMPOUNDS

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ supplemental to the Information Disclosure Statement filed January 17, 2007.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

☒ This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c) or 37 C.F.R. §1.97(d).

☒ A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO/SB/08A/B.


☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO/SB/08A/B form(s).

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-9587

Date: 8/17/11

Respectfully submitted,



---

Daniel Woods  
Attorney for Applicant  
Reg. No. 59,864